How is metabolic syndrome related to dyslipidemia?;Kako je metabolički sindrom povezan s dislipidemijom?

Biochemia Medica

Volumn 18, Issue 1, 2008, Pages 14-24

  Blaton, Victor H ^a   Korita, Irena ^b   Bulo, Anyla ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL CENTER MOTHER TERESA   (Albania)

Author keywords

Dyslipemia; HDL cholesterol; Metabolic syndrome

Indexed keywords

FATTY ACID; HIGH DENSITY LIPOPROTEIN; INSULIN RECEPTOR SUBSTRATE 1; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; EXERCISE; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 40749123594     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/bm.2008.003     Document Type: Review

References (14)

1. Reaven GM. The metabolic syndrome: What is in a name? Clin Chem 2006;52:5.
2. Reoven GM. The metabolic syndrome or the insuline resistance syndrome? Different names, different concepts, and different goals. Endorcinal Metab Clin N Am 2004;33;283-303.
3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
4. Despreées JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322:716-20.
5. Lamarche B, Tchernof A, Maurieége P, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955-61.
6. Assmann G, Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience) Am J Cardiol. 1992:70,733-7.
7. Mannienen V, Tekanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85.37-45
8. Donahue RP, Prineas RJ, Donahue RD, Zimmet P, Bean JA, De Courten M, et al. Is fasting leptin associated with insulin resistance among nondiabetic individuals? Diabetes Care 1999;22:1092-6.
9. El Harchaoul K, van der Steeg WA, Stroes J, Kastelein J. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective population study. J Am Coll Cordiol 2007;49(5):547-53.
10. Sacks FM. The apolipoprotein story. Atherosclerosis Supplements 2006;7:23-7.
11. Blaton V. Ox-LDL in function of metabolic syndrome components. Belgian Lipid Club 2005;6:4-5.
12. Haffner S. Diabetes and the metabolic syndrome - When is it best to intervene to prevent. Atherosclerosis supplements 2006;7:3-10.
13. Hu FB, Stampfer MJ, Haffner MJ. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002;25:1129-34.
14. Alexander CM, Haffner SM. NCEP defined metabolic syndrome, diabetes and prevalence of coronary heart disease. Diabetes 2003; 52(5); 1210-4.